Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 248

1.

Evaluation of Psychometric Properties of the Second Version of the Taqwa (Piety) Questionnaire in Bahasa Melayu.

Seghatoleslam T, Habil H, Hatim A, Ardakani A, Ishak K, Rashid R.

J Relig Health. 2017 Feb 10. doi: 10.1007/s10943-017-0362-8. [Epub ahead of print]

PMID:
28188463
2.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E.

Ann Oncol. 2016 Nov 10. doi: 10.1093/annonc/mdw561. [Epub ahead of print] No abstract available.

PMID:
28177066
3.

Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study.

Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E.

Ann Oncol. 2016 Nov 10. pii: mdw561. [Epub ahead of print]

PMID:
27836885
4.

Using Bayesian Adaptive Trial Designs for Comparative Effectiveness Research: A Virtual Trial Execution.

Luce BR, Connor JT, Broglio KR, Mullins CD, Ishak KJ, Saunders E, Davis BR; RE-ADAPT (REsearch in ADAptive methods for Pragmatic Trials) Investigators..

Ann Intern Med. 2016 Sep 20;165(6):431-8. doi: 10.7326/M15-0823.

PMID:
27273013
5.

Simulated Treatment Comparison of Time-To-Event (And Other Non-Linear) Outcomes.

Ishak KJ, Rael M, Phatak H, Masseria C, Lanitis T.

Value Health. 2015 Nov;18(7):A719. doi: 10.1016/j.jval.2015.09.2723. No abstract available.

6.

Simulation and matching-based approaches for indirect comparison of treatments.

Ishak KJ, Proskorovsky I, Benedict A.

Pharmacoeconomics. 2015 Jun;33(6):537-49. doi: 10.1007/s40273-015-0271-1.

PMID:
25795232
7.

A Statistical Modeling Framework To Characterize the Impact of Progression on Survival in Oncology.

Ishak KJ.

Value Health. 2014 Nov;17(7):A583. doi: 10.1016/j.jval.2014.08.1981. No abstract available.

8.

Methods for adjusting for bias due to crossover in oncology trials.

Ishak KJ, Proskorovsky I, Korytowsky B, Sandin R, Faivre S, Valle J.

Pharmacoeconomics. 2014 Jun;32(6):533-46. doi: 10.1007/s40273-014-0145-y.

PMID:
24595585
9.

Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study.

Connor JT, Luce BR, Broglio KR, Ishak KJ, Mullins CD, Vanness DJ, Fleurence R, Saunders E, Davis BR.

Clin Trials. 2013 Oct;10(5):807-27. doi: 10.1177/1740774513497293.

10.

Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.

Getsios D, Marton JP, Revankar N, Ward AJ, Willke RJ, Rublee D, Ishak KJ, Xenakis JG.

Pharmacoeconomics. 2013 Sep;31(9):767-80. doi: 10.1007/s40273-013-0070-5.

PMID:
23821436
11.

Overview of parametric survival analysis for health-economic applications.

Ishak KJ, Kreif N, Benedict A, Muszbek N.

Pharmacoeconomics. 2013 Aug;31(8):663-75. doi: 10.1007/s40273-013-0064-3. Review.

PMID:
23673905
12.

Improved perioperative blood pressure control leads to reduced hospital costs.

Getsios D, Wang Y, Stolar M, Williams G, Ishak KJ, Hu MY, Alvarez P, Crothers TA.

Expert Opin Pharmacother. 2013 Jul;14(10):1285-93. doi: 10.1517/14656566.2013.798646.

PMID:
23656583
13.

Accounting for the relationship between per diem cost and LOS when estimating hospitalization costs.

Ishak KJ, Stolar M, Hu MY, Alvarez P, Wang Y, Getsios D, Williams GC.

BMC Health Serv Res. 2012 Dec 1;12:439. doi: 10.1186/1472-6963-12-439.

14.

Optimizing the design of pragmatic trials: key issues remain.

Caro JJ, Ishak KJ.

J Comp Eff Res. 2012 Jul;1(4):319-27. doi: 10.2217/cer.12.37. Review.

PMID:
24237466
15.

Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale.

Allen MH, Daniel DG, Revicki DA, Canuso CM, Turkoz I, Fu DJ, Alphs L, Ishak KJ, Bartko JJ, Lindenmayer JP.

Innov Clin Neurosci. 2012 Jan;9(1):15-24.

16.

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.

Ishak KJ, Caro JJ, Drayson MT, Dimopoulos M, Weber D, Augustson B, Child JA, Knight R, Iqbal G, Dunn J, Shearer A, Morgan G.

Value Health. 2011 Jul-Aug;14(5):672-8. doi: 10.1016/j.jval.2011.02.1182.

17.

A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.

Xenakis JG, Kinter ET, Ishak KJ, Ward AJ, Marton JP, Willke RJ, Davies S, Caro JJ.

Pharmacoeconomics. 2011 Jun;29(6):497-510. doi: 10.2165/11589230-000000000-00000.

PMID:
21452908
18.

An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.

Getsios D, Blume S, Ishak KJ, Maclaine G, Hernández L.

Alzheimers Dement. 2012 Jan;8(1):22-30. doi: 10.1016/j.jalz.2010.07.001.

PMID:
21420366
19.

Costs and cost-effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: results from the SAPPHIRE trial.

Mahoney EM, Greenberg D, Lavelle TA, Natarajan A, Berezin R, Ishak KJ, Caro JJ, Yadav JS, Gray WA, Wholey MH, Cohen DJ.

Catheter Cardiovasc Interv. 2011 Mar 1;77(4):463-72. doi: 10.1002/ccd.22869.

PMID:
21351220
20.

No head-to-head trial? simulate the missing arms.

Caro JJ, Ishak KJ.

Pharmacoeconomics. 2010;28(10):957-67. doi: 10.2165/11537420-000000000-00000.

PMID:
20831304

Supplemental Content

Support Center